Back to top
more

Organogenesis (ORGO)

(Delayed Data from NSDQ)

$2.35 USD

2.35
903,642

+0.07 (2.84%)

Updated Apr 26, 2024 03:59 PM ET

After-Market: $2.35 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Organogenesis (ORGO) to Post Q3 Earnings: What's in Store?

On Organogenesis' (ORGO) upcoming third-quarter earnings call, investor focus is likely to be on the sales performance of its two segments - advanced wound care, and surgical & sports medicine.

Organogenesis (ORGO) Outpaces Stock Market Gains: What You Should Know

Organogenesis (ORGO) closed the most recent trading day at $10.98, moving +0.64% from the previous trading session.

Zacks.com featured highlights include: SunOpta, Citi Trends, Organogenesis, Tapestry and Venus Concept

Zacks.com featured highlights include: SunOpta, Citi Trends, Organogenesis, Tapestry and Venus Concept

Sanghamitra Saha headshot

Forget Bargains, Play 5 Stocks with Rising P/E Instead

Forget undervalued stocks, there is room for upside even in stocks with rising P/E.

Can Organogenesis (ORGO) Run Higher on Rising Earnings Estimates?

Organogenesis (ORGO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Organogenesis (ORGO) Q2 Earnings and Revenues Beat Estimates

Organogenesis (ORGO) delivered earnings and revenue surprises of 114.29% and 16.61%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Organogenesis (ORGO) Reports Next Week: Wall Street Expects Earnings Growth

Organogenesis (ORGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer Therapeutics

Zacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer Therapeutics

Kinjel Shah headshot

4 Small Drug Stocks Set to Escape the COVID-Led Industry Weakness

Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry in the second quarter of 2021. However, with demand trends expected to improve, XNCR, ORGO, CPIX, and ACER may prove to be good additions to one's portfolio.

Amryt (AMYT) NDA for Skin Disorder Drug Gets Priority Review

Amryt (AMYT) is seeking approval for Oleogel-S10 as a potential treatment for patients with rare and distressing genetic skin disorder, epidermolysis bullosa.

Verrica's (VRCA) Skin Disease Candidate Approval Gets Delayed

Verrica's (VRCA) NDA for lead candidate, VP-102, a drug-device combination treatment for skin disease, molluscum, is under review. FDA delays decision on potential approval for the candidate by three months.

Organogenesis (ORGO) Stock Jumps 7.7%: Will It Continue to Soar?

Organogenesis (ORGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Organogenesis (ORGO) Surpasses Q1 Earnings and Revenue Estimates

Organogenesis (ORGO) delivered earnings and revenue surprises of 275.00% and 18.83%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Organogenesis Holdings' (ORGO) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Organogenesis Holdings (ORGO).

Organogenesis (ORGO) Q4 Earnings and Revenues Top Estimates

Organogenesis (ORGO) delivered earnings and revenue surprises of 25.00% and 1.43%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Organogenesis (ORGO) Earnings Expected to Grow: Should You Buy?

Organogenesis (ORGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for Perrigo (PRGO) This Earnings Season?

Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.

Zacks Industry Outlook Highlights: Radius Health, USANA Health Sciences, Organogenesis Holdings, Turning Point Therapeutics and Oncternal Therapeutics

Zacks Industry Outlook Highlights: Radius Health, USANA Health Sciences, Organogenesis Holdings, Turning Point Therapeutics and Oncternal Therapeutics

Kinjel Shah headshot

5 Small Drug Stocks to Buy Amid Lingering COVID-Led Uncertainty

Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry in 2021. However, with demand trends expected to improve, USNA, RDUS, ONCT, ORGO and TPTX may prove to be good additions to one's portfolio.

Organogenesis Holdings' (ORGO) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Organogenesis Holdings (ORGO).

Aurinia (AUPH) Gets FDA Nod for Kidney Disorder Drug Lupkynis

Aurinia (AUPH) gets approval from the FDA for Lupkynis as a treatment for active lupus nephritis, a disease that causes irreversible kidney damage.

Earnings Estimates Rising for ORGANOGENESIS (ORGO): Will It Gain?

ORGANOGENESIS (ORGO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Corbus Pharmaceuticals (CRBP) Catches Eye: Stock Jumps 7.3%

Corbus Pharmaceuticals (CRBP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Sanghamitra Saha headshot

Why Nasdaq Can Win Again in 2021 After the Best Year Since 2009

New strain of coronavirus, growing demand for digitization and past record indicate that the Nasdaq can win in 2021 too after its best year since 2009.

Earnings Estimates Rising for Organogenesis (ORGO): Will It Gain?

Organogenesis (ORGO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.